The trusted source for
healthcare information and
The U.S. Food and Drug Administration reports that in an analysis of drug regulatory agencies of the four countries that account for 60% of global pharmaceutical sales, the United States outpaces them. The drugs included in the analysis were 214 new products introduced into the world market from 1990 to 1994.
When paired with the United Kingdom, the analysis showed that 58 of the 214 drugs had been approved by both the United Kingdom and the United States.
Although there were 29 drugs approved in the United Kingdom that weren’t approved in the United States, those drugs were not considered to be of major public health interest to U.S. patients.
When paired with Germany, the analysis found that 44 of the 214 new drugs had been approved in both countries, and when paired with Japan, 14 of the new drugs had been approved in both countries. But when the analysis looked at global drugs approved in more than one country, the United Kingdom and the United States outpaced Japan and Germany.
Forty-one drugs have been approved in three of the four countries, and of those, the United States approved 37% of them.